Page 1

Particulars Sun Pharmaceutical Industries Limited Registered Office : Sun Pharma Advanced Research Centre , Tandalja , Vadodara - 390012 . Corporate Office : Sun House , CTS No. 201 B / 1 , Western Express Highway , Goregaon ( E ) , Mumbai - 400063 Tel .: +91 22 4324 4324 . CIN : L24230GJ1993PLC019050 , Website : www.sunpharma.com Statement of Unaudited Consolidated Financial Results for the Quarter ended June 30 , 2021 Revenue from operations Quarter ended 30.06.2021 Unaudited 31.03.2021 Audited 30.06.2020 Unaudited ( In Million ) Year ended 31.03.2021 Audited a . Revenue from contracts with customers b . Other operating revenues Total revenue from operations ( I ) 96,694.3 493.1 97,187.4 84,637.4 74,858.2 592.4 85,229.8 994.3 75,852.5 332,330.8 2,650.6 334,981.4 II Other income 1,525.2 1,110.0 III Total income ( I + II ) 98,712.6 86,339.8 1,537.9 77,390.4 8,355.2 343,336.6 IV Expenses Cost of materials consumed 15,621.0 17,468.1 15,188.4 61,531.3 Purchases of stock - in - trade 9,631.4 7,418.2 6,833.2 31,751.7 Changes in inventories of finished goods , stock - in - trade and work - in - progress 1,241.9 ( 2,478.7 ) ( 2,325.6 ) ( 6,382.2 ) Employee benefits expense 17,587.4 16,774.5 17,590.4 68,622.3 Finance costs 350.9 301.0 519.5 1,414.3 Depreciation and amortisation expense 5,032.2 Other expenses 25,693.7 Net ( gain ) / loss on foreign currency transactions ( 798.8 ) 5,534.9 25,455.5 107.8 4,959.2 20,799.5 20,922.6 94,781.1 ( 791.6 ) ( 236.5 ) Total expenses ( IV ) 74,359.7 70,581.3 62,896.1 272,281.5 V Profit / ( loss ) before exceptional items and tax ( III - IV ) 24,352.9 15,758.5 14,494.3 71,055.1 VI Exceptional items ( Refer Note 4 ) 6,310.7 6,728.1 36,333.3 43,061.4 VII Profit / ( loss ) before tax ( V - VI ) VIII ( i ) Tax expense / ( credit ) for period / year 18,042.2 9,030.4 ( 21,839.0 ) 27,993.7 3,955.7 1,762.7 2,459.1 9,242.0 ( ii ) Tax expense / ( credit ) - Exceptional ( Refer Note 4 and 8 ) ( 1,212.3 ) ( 4,095.1 ) IX Profit / ( loss ) for the period before share of profit / ( loss ) of associates and joint venture ( VII - VIII ) 14,086.5 8,480.0 ( 24,298.1 ) 22,846.8 ㄨ ㄡ Share of profit / ( loss ) of associates and joint venture ( net ) ( 46.1 ) ( 55.9 ) Net Profit / ( loss ) after taxes and share of profit / ( loss ) of associates and joint venture but before non - controlling interests ( IX + X ) Non - controlling interests 14,040.4 8,424.1 35.8 ( 24,262.3 ) ( 123.3 ) 22,723.5 ( 401.3 ) ( 517.4 ) XII Net Profit / ( loss ) after taxes , share of profit / ( loss ) of associates and joint venture and non - controlling interests 14,441.7 8,941.5 ( 7,706.3 ) ( 16,556.0 ) ( 6,314.7 ) 29,038.2 XIII Other comprehensive income ( OCI ) A. ( i ) Items that will not be reclassified to profit or loss ( ii ) Income tax relating to items that will not be reclassified to profit or loss ( 935.7 ) ( 7.5 ) 2,158.4 B. ( i ) Items that may be reclassified to profit or loss 5,467.0 ( 156.7 ) ( 1,160.1 ) 61.0 ( 11.0 ) 3,233.9 ( 145.4 ) 3,892.1 ( 4,031.6 ) ( ii ) Income tax relating to items that may be reclassified to profit or loss 125.6 Total other comprehensive income ( A + B ) ( XIII ) 4,649.4 45.3 886.9 ( 231.6 ) ( 517.2 ) XIV Total comprehensive income for the period ( XI + XIII ) 18,689.8 9,311.0 3,710.5 ( 20,551.8 ) ( 1,460.3 ) 21,263.2 Attributable to : - Owners of the Company - Non - controlling interests 18,599.2 90.6 9,925.5 ( 13,198.4 ) 28,133.4 ( 614.5 ) ( 7,353.4 ) ( 6,870.2 ) XV Paid - up equity share capital - face value 1 each 2,399.3 2,399.3 2,399.3 2,399.3 XVI Other equity XVII Earnings per equity share of ₹ 1 each ( not annualised for quarters ) 462,228.5 ( Basic ) ( Diluted ) 6.0 88 6.0 3 3 3.7 3.7 ( 6.9 ) ( 6.9 ) 12.1 12.1 See accompanying notes to the unaudited consolidated financial results Research and development expenses incurred ( included above ) 5,748.1 5,386.5 4,151.9 21,028.2